{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:05:21Z","timestamp":1786993521378,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015170","name":"Yale SPORE in Lung Cancer","doi-asserted-by":"publisher","award":["P50-CA196530"],"award-info":[{"award-number":["P50-CA196530"]}],"id":[{"id":"10.13039\/100015170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001238","name":"Merck Company Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010900","name":"Yale Cancer Center","doi-asserted-by":"publisher","award":["P30-CA016359"],"award-info":[{"award-number":["P30-CA016359"]}],"id":[{"id":"10.13039\/100010900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["SU2C-AACR-DT17-15"],"award-info":[{"award-number":["SU2C-AACR-DT17-15"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jtho.2019.02.026","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T23:06:37Z","timestamp":1551913597000},"page":"1102-1108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Immune Checkpoint Inhibitor\u2013Associated Pericarditis"],"prefix":"10.1016","volume":"14","author":[{"given":"Mehmet","family":"Altan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Toki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott N.","family":"Gettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Carvajal-Hausdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Zugazagoitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Sinard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2019.02.026_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216228","article-title":"Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non\u2013small cell lung cancer","volume":"2016","author":"Gibson","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jtho.2019.02.026_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2019.02.026_bib3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1634\/theoncologist.2018-0157","article-title":"Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action","volume":"23","author":"Neilan","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2019.02.026_bib4","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jtho.2019.02.026_bib5","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2019.02.026_bib6","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtho.2019.02.026_bib7","first-page":"794842","article-title":"Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication","volume":"2015","author":"Yun","year":"2015","journal-title":"Case Rep Onocol Med"},{"key":"10.1016\/j.jtho.2019.02.026_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.02.026_bib9","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti\u2013PD-1 and anti\u2013PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.02.026_bib10","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2019.02.026_bib11","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jtho.2019.02.026_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","article-title":"CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes","volume":"101","author":"Love","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.jtho.2019.02.026_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124059","article-title":"Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153","volume":"10","author":"Baban","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jtho.2019.02.026_bib14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","article-title":"PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes","volume":"13","author":"Du","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.02.026_bib15","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1056\/NEJMcp1404070","article-title":"Clinical practice. Acute pericarditis","volume":"371","author":"LeWinter","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2019.02.026_bib16","article-title":"Profiling preexisting antibodies in patients treated with anti\u2013PD-1 therapy for advanced non\u2013small cell lung cancer","author":"Toi","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419301960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419301960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:38:34Z","timestamp":1761561514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086419301960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1556086419301960"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2019.02.026","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor\u2013Associated Pericarditis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2019.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}